Post-Market Surveillance for Overseas Registration of Medical Dressings: A Professional Guide

After a medical dressing is registered overseas, post-market surveillance (PMS) is not optional; it is an essential requirement for renewal, certificate maintenance, and response to regulatory inspections. Companies should begin with product classification and registration pathway, confirm the target country regulatory authority's specific requirements for post-market reports, adverse event reporting, site inspections, label changes, and annual updates. Then, establish an evidence chain covering technical documentation, quality management system, labeling and instructions for use, local representative responsibilities, and after-sales feedback. Common risks include ignoring local representative contract renewals, failing to report product changes in a timely manner, misusing CE or FDA marks, and lacking systematic vigilance data, which can lead to certificate suspension or product delisting.

Key Summary

For low- to medium-risk medical dressings, PMS is a mandatory lifecycle activity covering adverse event reporting, change notifications, surveillance audits, label updates, market feedback collection, and certificate maintenance. Companies often mistakenly believe that obtaining CE or FDA registration is the end of the project, but they later face deficiency letters during renewal or even export suspension due to unreported design changes. It is recommended to include PMS in the project budget from the initial registration stage, designate dedicated personnel to liaise with local representatives, and preserve production batch records, inspection records, complaint handling and clinical follow-up data. This enables reuse of the same evidence for multi-country registrations and reduces the risk of repetitive work and correction requests.

For Chinese medical device enterprises, a robust approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Target market registration simultaneously affects technical documentation, authorized representatives, importer cooperation, label language, quality system certificates, and subsequent change maintenance. If the initial work focuses only on 'which documents to submit', companies may encounter deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies integrate this issue into GHWP member states and multi-country market access strategies, using one set of reusable core technical documents to support localization across different markets, rather than recreating documentation for each country temporarily.

Applicable Scenarios and Core Issues

Obtaining an overseas registration certificate is only the starting point of entering a target market. PMS covers all dynamic activities from product launch to certificate expiry, including adverse event reporting, product change notifications, supervisory audits, labeling updates, market feedback collection, and certificate maintenance. Many enterprises mistakenly believe that having a CE or FDA registration number is enough; however, they may later receive deficiency notifications during renewal or even have exports suspended for failing to report design changes.

This article applies to three scenarios: (1) manufacturers that already have CE, FDA, or NMPA certificates and are planning to apply to GHWP member states or other countries; (2) manufacturers that have completed registration in Southeast Asia, the Middle East, Latin America, and need to develop an annual maintenance plan; (3) traders or brand owners that accept OEM or private-label orders and need to clarify the responsibilities of the certificate holder, manufacturer, and local representative.

The core question of PMS is not 'whether it is necessary', but 'how to demonstrate continuous compliance'. Regulatory authorities focus not only on whether a company has complete internal audit files, but also on whether it continuously collects safety and effectiveness data during actual product sales, takes appropriate actions when risks are identified, and updates registration documents in a timely manner.

For medical dressings of low to medium risk, PMS typically focuses on product labeling, biocompatibility re-evaluation, reuse or sterilization batch records, and infection related adverse events. Companies should combine these requirements with the laws, regulations, guidelines and industry standards of the registration country to establish traceable records.

Another easily overlooked issue is that market feedback after overseas launch may not always align with design verification data from the development phase. Differences in ambient temperature and humidity, local dressing habits, logistics and storage conditions in different countries may lead to actual clinical performance variations. Companies cannot rely only on domestic usage data; they must establish dedicated data collection channels for each target market.

Therefore, when developing a PMS plan, a company should first answer four questions: (1) What regulatory classification does the product fall into in the target country and which regulations apply? (2) Who holds the registration certificate or authorization document and is a local representative required? (3) Do the current technical documents and risk management reports cover the changed version? (4) In what format should data arising from surveillance activities be retained, and can it be quickly provided during renewal or inspection?

Registration Decision Logic

The scope of PMS depends largely on the product classification and regulatory pathway at the time of registration. Different countries have different classifications for medical dressings, which directly affect certificate validity, renewal cycles, and reporting obligations.

The first step is to determine whether the product falls within the scope of medical device regulation in the target country. Medical dressings may be classified as medical devices, drug-device combination products, or even ordinary cosmetics or disinfectants in different countries. A wrong classification will invalidate all subsequent PMS activities.

The second step is to determine the risk class and registration pathway. For example, under the EU MDR, wound dressings are usually Class I or IIa, requiring conformity assessment through notified body certification or self-declaration. Under the US FDA, they are categorized as Class I or II, and some products may require a 510(k). In GHWP member states such as Saudi Arabia, Thailand, and Brazil, there are also different risk classifications and registration routes.

The third step is to evaluate whether existing documents can be reused. Existing NMPA registration certificates, CE certificates, FDA 510(k) clearances, ISO 13485 certificates, and MDSAP certificates all demonstrate that the quality management system and production processes comply with internationally accepted requirements and are core documents for overseas registration. However, certificates cannot replace PMS; regulators are more concerned with whether the products covered by the certificate are consistent with the actual versions on the market.

The fourth step is to confirm technical documentation, performance verification, risk management, clinical evaluation or clinical evidence, labeling and instructions, local agent, authorized representative, and post-market maintenance requirements. These elements do not need to be built from scratch. Through gap analysis, existing documents can be converted to meet target country requirements.

For multi-country registration, companies should establish a 'core document package' containing product technical parameters, risk management report, biocompatibility testing, sterilization validation, clinical evaluation and label drafts. Using this baseline, add local representative information, interpretation of local standard deviations, and additional tests required by the approving authority for each target market.

The implementation pathway for PMS must also comply with target country regulations. Some countries accept PMS reports as a prerequisite for renewal, others require annual updates, and some conduct periodic market inspections to assess compliance. Companies should develop an annual calendar based on registration pathway requirements, integrating internal audits, management reviews, adverse event analysis, and customer feedback into a fixed surveillance process.

Documentation and Evidence

PMS documentation can be divided into four categories: technical documentation update records, quality management system evidence, market surveillance data, and registration certificate maintenance documents. Each category should have version control, approval records, and archiving paths.

1. Technical documentation update records: This includes product design change notices, labeling and instruction version changes, raw material supplier change records, production process adjustment proofs, supplementary stability or aging test reports, and sterilization validation re-confirmation reports. Changes in the material formulation, hydrophilic coating, backing material, or adhesive used in medical dressings should be updated in the risk management files promptly.

2. Quality management system evidence: This includes ISO 13485 internal audit reports, management review minutes, corrective and preventive actions (CAPA), supplier audit records, nonconforming product handling, and employee training files. This evidence is generally common across domestic and overseas operations, but attention should be paid to whether the language of records meets target country requirements.

3. Market surveillance data: This includes customer complaint logs, adverse event reports, reports of death or serious injury, on-site sampling inspection records, product recall records, return analysis, low- or high-temperature logistics validation, and market sample test results. Complete batch records and batch inspection reports should be retained for every exported batch.

4. Registration certificate maintenance documents: This includes local agent authorization agreements, authorized representative change notifications, copies of registration certificates, renewal application records, change submission receipts, annual fee payment vouchers, and notifications of registration information updates. These documents should be retained for at least the certificate validity period plus the traceability period.

To satisfy cross-border inspections, it is best to establish a separate PMS file for each overseas registered model and translate the file index into English or the official language of the target country. The same dressing may be sold under different registration numbers in different countries; if files are mixed, gaps may be found during inspection.

It is worth noting that clinical evaluation or clinical evidence is equally important in PMS. If a product relied on literature or equivalence comparison at the time of registration, authorities may require real-world data at renewal. Companies should plan product follow-up programs with medical institutions in advance to collect key indicators such as healing time, infection rate, and allergic reactions.

All PMS documents should be linked to product batch numbers. When a regulatory authority requests traceability information for a given batch, the company should be able to retrieve batch production records, inspection records, and sales distribution records within 24 hours.

Common Mistakes

• Treating the registration certificate as the end of the project and failing to establish an annual maintenance team, resulting in inability to find original documents at renewal.
• Ignoring the role of the local representative, not assessing their regulatory capability, or using an unqualified trader as a representative, eventually leading to certificate revocation due to representative negligence.
• Failing to assess whether a product design change requires re-registration, such as changing the dressing substrate or adding an active ingredient, and continuing to sell under the original certificate, which may be considered an unauthorized change.
• Making labeling errors, such as incorrect language, incorrect dimensions, or omitting the unique device identifier (UDI) requirement, resulting in detention or market inspection violations.
• Lacking a process for adverse event reporting; failing to submit reports to the regulatory authority within the legal deadline after customer complaints, leading to fines or loss of registration.
• Believing that CE or FDA registration covers other markets and neglecting special requirements for local representatives and local testing in the Middle East and Southeast Asia.
• Using different versions of technical documents for multi-country registration without a document difference comparison table, causing repeated submissions of wrong versions during deficiency responses.
• Storing PMS data in a fragmented manner without annual consolidation, making it impossible to respond to unannounced inspections.

Company Preparation Checklist

To prepare effectively, companies should take the following actions:

• Assign a PMS responsible person and clearly define their duties, authority, and reporting lines to management.
• Map the target country's regulatory reporting timelines, update cycles, and site inspection requirements into a written table.
• Establish a product change assessment procedure to ensure any change in design, material, process, label, or supplier triggers a change assessment.
• Re-sign or supplement authorization agreements with local representatives, clearly defining their responsibilities in adverse event reporting, certificate maintenance, and regulatory communication.
• Establish batch retention sample system for exported products, retaining key performance testing items and samples for at least one year beyond the shelf life.
• Create a complaint log that distinguishes ordinary user feedback from serious adverse events, and set a closed-loop processing deadline for each complaint.
• Keep up-to-date versions of ISO 13485 certificates, management review reports, and internal audit reports, and translate them into the target country's language.
• Prepare a product technical document index including version records of risk analysis, biocompatibility testing, sterilization validation, and clinical evaluation.
• Conduct an annual PMS compliance self-check against registration requirements and standard clauses.
• Develop a renewal calendar, checking certificate expiry dates and required update materials at least one year in advance.

AIMEILI's Perspective

In our experience with medical dressing companies, the most common mistake is applying the mindset of domestic or CE registration directly to other overseas markets. For example, in Saudi Arabia or Brazil, the authorization scope of local representatives, the intensity of site inspections, and the notarization requirements for document updates are significantly different from those in the EU or China. Companies often discover only two months before renewal that the representative contract has expired or documents lack notarization.

At the early stage of a project, the most important task is not to submit documents urgently, but to spend time on a gap analysis of the registration pathway and PMS obligations. Organize the target country's regulatory framework, product classification, certificate validity, representative requirements, reporting deadlines, and inspection mechanisms into an internal compliance map. This map directly affects subsequent resource investment and staffing.

Among technical documents, production validation, ISO 13485 certificates, biocompatibility reports, and sterilization validation are usually reusable across markets. However, risk management reports must be re-assessed based on the target market. Factors such as user population, medical practices, environmental humidity, and concomitant medication use may differ by country. Labeling and instructions for use must not be directly translated; units of measurement, warning statements, storage conditions, and local graphic symbols must be adjusted according to local regulations.

Local representatives and certificate control are two lifelines in overseas registration. The local representative is responsible not only for receiving regulatory notifications, but also for adverse event reporting and cooperating with site inspections. If the representative is incompetent or changes frequently, document handover omissions and regulatory communication interruptions can occur. Companies should personally keep the registration certificate, a complete copy of technical documents, and account information to ensure that the registration status is maintained even if the representative is changed.

For multi-country registration, the most effective way to reduce repetitive work and correction risk is to establish a two-layer structure consisting of a core document package and a country-specific difference layer. The core document package remains consistent, while each country maintains only a difference comparison table listing the local representative, additional tests, translation notarization, fee cycles, and report formats. This approach prevents divergence in registration files across countries and enables rapid generation of dedicated file sets during renewal or change.

PMS is not a passive burden but a productive tool for companies to achieve sustained exports and brand trust. The more comprehensive the data collection, the more confident the company will be during renewal and the more prepared during regulatory inspections. By performing surveillance proactively, companies can devote more energy to developing new markets.

Common Follow-up Questions

Is there a fixed PMS template for medical dressings under the EU MDR?

No single fixed template is mandated. The EU MDR incorporates PMS requirements into the regulation but allows manufacturers to design their own system. Companies may refer to guidelines such as MDCG 2021-9 to establish PMS plans and reports and integrate them with the adverse event reporting system, trend reports, and periodic safety update reports. For Class I and IIa dressings, companies should at least set surveillance frequencies based on the risk class and maintain traceable records.

If a product is only exported to a Middle Eastern country, can the CE certificate be used for PMS maintenance?

No, it cannot be used directly. CE certificates are only valid in the European Economic Area and certain mutual recognition countries. Middle Eastern countries such as Saudi Arabia and the UAE have their own medical device registration systems and local representative requirements. Although CE technical documents can serve as a technical basis, the company must complete local registration and comply with additional local requirements, such as labeling, language, halal status, or special sensitive-skin considerations.

If a company changes its local representative, do PMS documents need to be resubmitted?

Typically, you do not need to resubmit all technical documents, but you must notify the regulatory authority of the representative change, update the authorization letter, and transfer PMS responsibilities to the new representative. The outgoing representative is obliged to hand over all customer complaints, adverse event records, and regulatory correspondence, and the new representative must confirm receipt within the legal deadline. The company should retain records of communications before and after the change for audit purposes.

Source and Applicability

Author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Preference is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supplementary references.

Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It is not a substitute for the official requirements of the target country's regulatory authority, test conclusions, or legal opinions.

Compiled based on AIMEILI's registration practice database, the medical device international registration knowledge base, and public regulatory information. For specific projects, the latest requirements of the target country's regulatory authority and the product documentation basis shall prevail. Published: 2026-08-30 16:17. Updated: 2026-08-30 16:17.